Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in sickle cell disease
PACTR202505901903077Phase 3Not yet recruiting
- Sponsor
- Sanofi
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3 trial of rilzabrutinib in sickle cell disease (SCD) (2 arms), sponsored by Sanofi. Primary endpoint: Annualized rate of clinical vaso-occlusive crises. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
rilzabrutinib
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202505901903077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202505901903077.